Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome

Cancer

Volumn 117, Issue 24, 2011, Pages 5476-5484

  Gong, Yun ^a   Huo, Lei ^a   Liu, Ping ^a   Sneige, Nour ^a   Sun, Xiaoping ^a   Ueno, Naoto T ^a   Lucci, Anthony ^a   Buchholz, Thomas A ^a   Valero, Vicente ^a   Cristofanilli, Massimo ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

enhancer of zeste homolog 2; estrogen receptor; human epidermal growth factor receptor 2; inflammatory breast cancer; survival

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; PACLITAXEL; POLYCOMB GROUP PROTEIN; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR EZH2; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER GRADING; CANCER RADIOTHERAPY; CAUCASIAN; COHORT ANALYSIS; FOLLOW UP; HISPANIC; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MASTECTOMY; MICROARRAY ANALYSIS; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RACE DIFFERENCE; TRIPLE NEGATIVE BREAST CANCER; UNIVARIATE ANALYSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BREAST NEOPLASMS; MASTECTOMY; MICROARRAY ANALYSIS; MIDDLE AGED; NEOADJUVANT THERAPY; REPRESSOR PROTEINS; RETROSPECTIVE STUDIES; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 82555176159     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26179     Document Type: Article

References (41)

1. Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH,. Trends in inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results Program at the National Cancer Institute. J Natl Cancer Inst. 2005; 97: 966-975. (Pubitemid 41430562)
2. Gonzalez-Angulo AM, Hennessy BT, Broglio K, et al. Trends for inflammatory breast cancer: is survival improving? Oncologist. 2007; 12: 904-912. (Pubitemid 47359132)
3. Cristofanilli M, Valero V, Buzdar AU, et al. Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer. 2007; 110: 1436-1444. (Pubitemid 47463056)
4. Boyer LA, Plath K, Zeitlinger J, et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature. 2006; 441: 349-353. (Pubitemid 44050199)
5. Gil J, Bernard D, Peters G,. Role of polycomb group proteins in stem cell self-renewal and cancer. DNA Cell Biol. 2005; 24: 117-125. (Pubitemid 40189747)
6. Jorgensen HF, Giadrossi S, Casanova M, et al. Stem cells primed for action: polycomb repressive complexes restrain the expression of lineage-specific regulators in embryonic stem cells. Cell Cycle. 2006; 5: 1411-1414. (Pubitemid 44153649)
7. Pietersen AM, van Lohuizen M,. Stem cell regulation by polycomb repressors: postponing commitment. Curr Opin Cell Biol. 2008; 20: 201-207.
8. Rajasekhar VK, Begemann M,. Concise review: roles of polycomb group proteins in development and disease: a stem cell perspective. Stem Cells. 2007; 25: 2498-2510. (Pubitemid 47582742)
9. Roman-Trufero M, Mendez-Gomez HR, Perez C, et al. Maintenance of undifferentiated state and self-renewal of embryonic neural stem cells by polycomb protein Ring1B. Stem Cells. 2009; 27: 1559-1570.
10. Sauvageau M, Sauvageau G,. Polycomb group genes: keeping stem cell activity in balance [serial online]. PLoS Biol. 2008; 6: e113.
11. Valk-Lingbeek ME, Bruggeman SW, van Lohuizen M,. Stem cells and cancer; the polycomb connection. Cell. 2004; 118: 409-418. (Pubitemid 39485661)
12. Kirmizis A, Bartley SM, Farnham PJ,. Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy. Mol Cancer Ther. 2003; 2: 113-121.
13. Collett K, Eide GE, Arnes J, et al. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res. 2006; 12: 1168-1174. (Pubitemid 43342505)
14. Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A. 2003; 100: 11606-11611. (Pubitemid 37205983)
15. Reijm EA, Jansen MP, Ruigrok-Ritstier K, et al. Decreased expression of EZH2 is associated with up-regulation of ER and favorable outcome to tamoxifen in advanced breast cancer. Breast Cancer Res Treat. 2011; 125: 387-394.
16. Raaphorst FM, Meijer CJ, Fieret E, et al. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia. 2003; 5: 481-488. (Pubitemid 38045085)
17. Bachmann IM, Halvorsen OJ, Collett K, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol. 2006; 24: 268-273. (Pubitemid 46622055)
18. Raaphorst FM, van Kemenade FJ, Blokzijl T, et al. Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease. Am J Pathol. 2000; 157: 709-715. (Pubitemid 32109362)
19. Visser HP, Gunster MJ, Kluin-Nelemans HC, et al. The polycomb group protein EZH2 is up-regulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol. 2001; 112: 950-958. (Pubitemid 32322920)
20. Matsukawa Y, Semba S, Kato H, Ito A, Yanagihara K, Yokozaki H,. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci. 2006; 97: 484-491. (Pubitemid 43811589)
21. Sudo T, Utsunomiya T, Mimori K, et al. Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer. 2005; 92: 1754-1758. (Pubitemid 40756488)
22. Hoffmann MJ, Engers R, Florl AR, Otte AP, Muller M, Schulz WA,. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer. Cancer Biol Ther. 2007; 6: 1403-1412. (Pubitemid 351590350)
23. van Leenders GJ, Dukers D, Hessels D, et al. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol. 2007; 52: 455-463. (Pubitemid 46963432)
24. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002; 419: 624-629.
25. McHugh JB, Fullen DR, Ma L, Kleer CG, Su LD,. Expression of polycomb group protein EZH2 in nevi and melanoma. J Cutan Pathol. 2007; 34: 597-600. (Pubitemid 47063232)
26. Raman JD, Mongan NP, Tickoo SK, Boorjian SA, Scherr DS, Gudas LJ,. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res. 2005; 11: 8570-8576. (Pubitemid 43005902)
27. Ding L, Erdmann C, Chinnaiyan AM, Merajver SD, Kleer CG,. Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues. Cancer Res. 2006; 66: 4095-4099.
28. Gonzalez ME, Li X, Toy K, et al. Down-regulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene. 2009; 28: 843-853.
29. Pietersen AM, Horlings HM, Hauptmann M, et al. EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer [serial online]. Breast Cancer Res. 2008; 10: R109.
30. Zeidler M, Varambally S, Cao Q, et al. The polycomb group protein EZH2 impairs DNA repair in breast epithelial cells. Neoplasia. 2005; 7: 1011-1019.
31. Ding L, Kleer CG,. Enhancer of zeste 2 as a marker of preneoplastic progression in the breast. Cancer Res. 2006; 66: 9352-9355. (Pubitemid 44623628)
32. Cao R, Wang L, Wang H, et al. Role of histone H3 lysine 27 methylation in polycomb-group silencing. Science. 2002; 298: 1039-1043. (Pubitemid 35247314)
33. Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D,. Histone methyltransferase activity associated with a human multiprotein complex containing the enhancer of zeste protein. Genes Dev. 2002; 16: 2893-2905. (Pubitemid 35334738)
34. Shi B, Liang J, Yang X, et al. Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol Cell Biol. 2007; 27: 5105-5119. (Pubitemid 47068285)
35. Sun F, Chan E, Wu Z, Yang X, Marquez VE, Yu Q,. Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells. Mol Cancer Ther. 2009; 8: 3191-3202.
36. Zeidler M, Kleer CG,. The polycomb group protein enhancer of zeste 2: its links to DNA repair and breast cancer. J Mol Histol. 2006; 37: 219-223. (Pubitemid 44795625)
37. Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N, Rotter V,. Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene. 2004; 23: 5759-5769. (Pubitemid 39093021)
38. Cao P, Deng Z, Wan M, et al. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta [serial online]. Mol Cancer. 2010; 9: 108.
39. Varambally S, Cao Q, Mani RS, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 2008; 322: 1695-1699.
40. Wong CF, Tellam RL,. MicroRNA-26a targets the histone methyltransferase enhancer of zeste homolog 2 during myogenesis. J Biol Chem. 2008; 283: 9836-9843.
41. Kota J, Chivukula RR, O'Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 2009; 137: 1005-1017.